Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 26, 2009

Tocris to Market Two AstraZeneca Compounds as Preclinical Cancer Research Tools

  • Tocris Bioscience obtained exclusive rights from AstraZeneca to supply two anticancer agents, anastrozole and bicalutamide, as preclinical research compounds.  Anastrozole is an aromatase inhibitor, and bicalutamide is an androgen inhibitor.

    “By making the fully licensed products available through our catalogue, we hope to promote new and exciting research in the fundamental processes that drive cancer development,” says Duncan Crawford, Tocris’ CSO.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »